Status:
UNKNOWN
Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test
Lead Sponsor:
Azienda Ospedaliera San Giovanni Battista
Collaborating Sponsors:
Humanitas Hospital, Italy
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-110 years
Brief Summary
The aim of the project is to corroborate them on a large retrospective cohort of HGS-EOC and confirm the possibility of identify TP53 mutations in high grade endometrioid tumors. This will consequent...
Detailed Description
All participating women will be identified through the ovarian cancer audit implemented by the "Oncological Network of Piedmont and Valle d'Aosta" and the Clinical Epidemiology Unit of CPO Piemonte be...
Eligibility Criteria
Inclusion
- age ≥18 years;
- confirmed histologic diagnosis of HGS-EOC or high grade endometrioid tumor;
- presence of one FFPE primary tumor biopsy with at least 40% of tumor cells based on Hematoxylin and Eosin staining, in the archive of the Pathology Departments of the hospital centers where they have been treated;
- presence of one or more Pap Tests sampled up to eight years before EOC diagnosis during routine cervical cancer screening;
- negative history for other gynecologic malignancies;
Exclusion
- pap test not available in patients with ovarian cancer
Key Trial Info
Start Date :
April 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT04812938
Start Date
April 12 2021
End Date
October 1 2022
Last Update
March 24 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Biomedical Sciences - Humanitas University
Milan, Italy, 20089
2
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Turin, Italy, 10100